Global state: any change in global state – unspecified problem necessitating change in dose or type of antipsychotics – medium term · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes global state: any change in global state – unspecified problem… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher clinically significant response: important change As defined by each… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Behavioural problems: agitation or aggression · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher adverse events: Sedation Number of participants with… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in adverse events: Weight gain Number of participants with weight gain compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
Weight gain (equal or greater then 7% of baseline) · people with psychosis
1 finding from 1 review
High prolactin at any time during treatment · people with psychosis
1 finding from 1 review
Change in corrected QT · people with psychosis
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes adverse events: gastrointestinal – dyspeptic symptoms –… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: change in hospital status – any change · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes service use: change in hospital status – any change compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines + antipsychotics changes tranquillisation or asleep: sedation ‐ medium term ‐ +/vs… compared with same antipsychotics (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in global state: no improvement ‐ +/vs haloperidol ‐ medium term As… compared with same antipsychotics (low certainty).
1 finding from 1 review